SCHEMBL3383480

SCHEMBL3383480

CCC(CCCCCC(=O)c1ccc(-c2ccsc2)cc1)C(=O)O

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 1/20 0.46
MMP9 P14780 1/20 0.46
MMP8 P22894 1/20 0.46
HDAC1 Q13547 3/20 0.40
HDAC8 Q9BY41 1/20 0.40
L3MBTL1 Q9Y468 3/20 0.40
HPGD P15428 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
HDAC6 Q9UBN7 2/20 0.39
HSD17B3 P37058 5/20 0.39
MME P08473 3/20 0.38
LMNA P02545 1/20 0.38
MAPT P10636 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
CA2 P00918 1/20 0.38
MAPK1 P28482 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3381679 0.83 HDAC1 (0.57) HDAC1HDAC8L3MBTL1HPGDSMN1; SMN2
SCHEMBL3381919 0.81 HDAC1 (0.56) MMP2MMP9MMP8HDAC1HDAC8
SCHEMBL3383975 0.81 PDE4B (0.55) MMP2MMP9MMP8HDAC1HDAC8
SCHEMBL3384356 0.77 HDAC1 (0.53) HDAC1HDAC8L3MBTL1HPGDSMN1; SMN2
SCHEMBL4305421 0.77 MMP2 (0.49) MMP2MMP9MMP8HDAC1HDAC8
SCHEMBL8534645 0.73 SMN1; SMN2 (0.64) MMP2MMP9MMP8HDAC1L3MBTL1
SCHEMBL12670300 0.73 SMN1; SMN2 (0.59) MMP2MMP9MMP8L3MBTL1HPGD
SCHEMBL7869590 0.72 MMP2 (0.46) MMP2MMP9MMP8MMEMAPT
SCHEMBL3379506 0.72 HDAC1 (0.61) HDAC1HDAC8L3MBTL1HPGDSMN1; SMN2
SCHEMBL3383993 0.71 HDAC1 (0.59) HDAC1HDAC8L3MBTL1HPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1280764-B1 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC (CA) 2010-11-24 EP disclosed
US-20090181971-A1 Inhibitors of Histone Deacetylase METHYLGENE INC. 2009-07-16 US disclosed
US-7288567-B2 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2007-10-30 US disclosed
EP-1524262-A1 Inhibitors of histone deacetylase Methylgene, Inc. (CA) 2005-04-20 EP disclosed
EP-1280764-A2 INHIBITORS OF HISTONE DEACETYLASE Methylgene, Inc. (CA) 2003-02-05 EP disclosed
US-20020115826-A1 Inhibitors of histone deacetylase 92229129 QUEBEC INC. (CA) 2002-08-22 US disclosed
WO-2001070675-A2 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE, INC. (CA) 2001-09-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020115826-A1 Inhibitors of histone deacetylase HDAC1, HDAC5, HDAC3 MMP2 408/4885MMP9 169/4885MMP8 636/4885
US-20090181971-A1 Inhibitors of Histone Deacetylase HDAC1, HDAC5, HDAC3 MMP2 408/4885MMP9 169/4885MMP8 636/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.